Search for a command to run...
Around 850 million people currently are affected by different types of kidney disorders.1 Up to one in 10 adults worldwide has chronic kidney disease (CKD), which is invariably irreversible and mostly progressive. The global burden of CKD is increasing, and CKD is projected to become the fifth most common cause of years of life lost globally by 2040.2 If CKD remains uncontrolled and if the affected person survives the ravages of cardiovascular and other complications of the disease, CKD progresses to end-stage renal disease, where life cannot be sustained without dialysis therapy or kidney transplantation. Hence, CKD is a major cause of catastrophic health expenditure.3 The costs of dialysis and transplantation consume 2–3% of the annual healthcare budget in high-income countries, spent on less than 0.03% of the total population of these countries.4 Importantly, however, kidney disease can be prevented and progression to end-stage renal disease can be delayed with appropriate access to basic diagnostics and early treatment including lifestyle modifications and nutritional interventions.4-8 Despite this, access to effective and sustainable kidney care remains highly inequitable across the world, and kidney disease a low health priority in many countries. Kidney disease is crucially missing from the international agenda for global health. Notably absent from the impact indicators for the Sustainable Development Goal: Goal 3. Target 3.4: By 2030 (By 2030, reduce by one-third premature mortality from non-communicable diseases (NCD) through prevention and treatment and promote mental health and well-being) and the latest iteration of the United Nation Political Declaration on NCD. Kidney diseases urgently need to be given political attention, priority and consideration.9 CKD is a major risk factor for heart disease and cardiac death, as well as for infections such as tuberculosis, and is a major complication of other preventable and treatable conditions including diabetes, hypertension, human immunodeficiency virus and hepatitis.4-7 As the Sustainable Development Goals and Universal Health Coverage agendas progress and provide a platform for raising awareness of NCD healthcare and monitoring needs, targeted action on kidney disease prevention should become integral to the global policy response.1 According to the expert definitions including the Center for Disease Control and Prevention,10 the term ‘prevention’ refers to activities that are typically categorised by the following three definitions: (1) Primary Prevention implies intervening before health effects occur in an effort to prevent the onset of illness or injury before the disease process begins; (2) Secondary Prevention suggests preventive measures that lead to early diagnosis and prompt treatment of a disease to prevent more severe problems developing and includes screening to identify diseases in the earliest stages and (3) Tertiary Prevention indicates managing disease after it is well established in order to control disease progression and the emergence of more severe complications, which is often by means of targeted measures such as pharmacotherapy, rehabilitation and screening for and management of complications. These definitions have important bearing in the prevention and management of the CKD, and accurate identification of risk factors that cause CKD or lead to faster progression to renal failure as shown in Figure S1 (Supporting Information) are relevant in health policy decisions and health education and awareness related to CKD.11 Measures to achieve effective primary prevention should focus on the two leading risk factors for CKD including diabetes mellitus and hypertension. Other CKD risk factors include polycystic kidneys or other congenital or acquired structural anomalies of the kidney and urinary tracts, primary glomerulonephritis, exposure to nephrotoxic substances or medications (such as non-steroidal anti-inflammatory drugs), having one single kidney, for example, solitary kidney after cancer nephrectomy, high dietary salt intake, inadequate hydration with recurrent volume depletion, heat stress, exposure to pesticides and heavy metals (as has been speculated as the main cause of Mesoamerican Nephropathy), and possibly high protein intake in those at higher risk of CKD.8 Among non-modifiable risk factors are advancing age and genetic factors such as apolipoprotein 1 (APOL1) gene that is mostly encountered in those with sub-Saharan African ethnicity, especially among African Americans. Table S1 shows some of the risk factors of CKD. Among measures to prevent emergence of de novo CKD are screening efforts to identify and manage persons at high risk of CKD, especially those with diabetes mellitus and hypertension. Hence, targeting primordial risk factors of these two conditions including metabolic syndrome and overnutrition is relevant to primary CKD prevention as is correcting obesity.12 Promoting healthier lifestyle includes physical activity and healthier diet. The latter should be based on more plant-based foods with less meat, less sodium intake, more complex carbohydrates with higher fibre intake and less saturated fat. In those with hypertension and diabetes, optimising blood pressure and glycaemic control has shown to be effective in preventing diabetic and hypertensive nephropathies. Persons with solitary kidney should avoid high protein intake above 1 gram per kilogram body weight per day.13, 14 Obesity should be avoided, and weight reduction strategies should be considered.12 Evidence suggests that among those with CKD, the vast majority have early-stage of the disease, that is, CKD Stages 1 and 2 with microalbuminuria (30–300 mg/day) or CKD Stage 3B (e Glomerular filtration rate (eGFR) between 45 and 60 mL/min/1.73 m2).14 For these earlier stages of CKD, the main goal of kidney health education and clinical interventions for ‘secondary prevention’ is how to slow disease progression. Uncontrolled or poorly controlled hypertension is one of the most established risk factors for faster CKD progression. The cornerstone of the pharmacotherapy in secondary prevention is the renin–angiotensin–aldosterone system inhibitors. Low protein diet appears to have a synergistic effect on renin–angiotensin–aldosterone system inhibitor therapy.15 Recent data suggest that a new class of anti-diabetic medications known as sodium-glucose cotransporter-2 inhibitors can slow CKD progression, but this effect may not be related to glycaemic modulation of the medication.16 Whereas acute kidney injury (AKI) may or may not cause de novo CKD, AKI events that are superimposed on pre-existing CKD may accelerate disease progression.17 A relatively recent case of successful secondary prevention that highlights the significance of implementing preventive strategies in CKD is the use of a vasopressin V(2)-receptor antagonists in adult polycystic kidney disease.18 In patients with advanced CKD, management of uraemia and related comorbid conditions such as anaemia, mineral and bone disorders and cardiovascular disease is of high priority, so that these patients can continue to achieve highest longevity. Whereas many of these patients will eventually receive renal replacement therapy in the form of dialysis therapy or kidney transplantation, a new trend is emerging to maintain them longer without dialysis by implementing conservative management of CKD. The lack of awareness of CKD around the world is one of the reasons for late presentation of CKD in both developed and developing economies.19-21 The overall CKD awareness among general population and even high cardiovascular risk groups across 12 low-income and middle-income countries was less than 10%.21 Given its asymptomatic nature, screening of CKD plays an important role in early detection. Consensus and positional statements have been published by International Society of Nephrology,22 National Kidney Foundation,23 Kidney Disease Improving Global Outcomes,24 NICE Guidelines25 and Asian Forum for CKD Initiatives.26 There was lack of trials to evaluate screening and monitoring of CKD.27 Currently most will promote a targeted screening approach to early detection of CKD. Some of the major groups at risk for targeted screening includes: patients with diabetes, hypertension, those with family history of CKD, individuals receiving potentially nephrotoxic drugs, herbs or substances or taking indigenous medicine, patients with past history of AKI and individuals older than 65 years.26, 28 CKD can be detected with two simple tests: a urine test for the detection of proteinuria and a blood test to estimate the glomerular filtration rate.23, 26 Given that currently a population screening for CKD is not recommended and it was claimed that it might add unintended harm to the general population being screened,27 there is no specialty society or preventive services group which recommends general screening.29 Low-income to middle-income countries are ill-equipped to deal with the devastating consequences of CKD, particularly the late stages of the disease. There are suggestions that screening should primarily include high-risk individuals, but also extend to those with suboptimal levels of risk, for example, prediabetes and prehypertension.30 Universal screening of the general population would be time-consuming, expensive and has been shown to be not cost-effective. Unless selectively directed towards high-risk groups, such as the case of CKDu in disadvantaged populations.31 According to a cost-effectiveness analysis using a Markov decision analytic model, population-based dipstick screening for proteinuria has an unfavourable cost-effectiveness ratio.32 From an economic perspective, screening CKD by detection of proteinuria was shown to be cost-effective in patients with hypertension or diabetes in a systematic review.33 CKD screening may be more cost-effective in populations with higher incidences of CKD, rapid rates of progression and more effective drug therapy. The approach towards CKD early detection will include the decision for frequency of screening, who should perform the screening and intervention after screening.22 Screening frequency for targeted individuals should be yearly if no abnormality is detected on initial evaluation. This is in line with the Kidney Disease Improving Global Outcomes resolution that the frequency of testing should be according to the target group to be tested and generally need not be more frequent than once per year.24 Who should perform the screening is always a question especially when the healthcare professional availability is a challenge in lower income economies. Physicians, nurses, paramedical staff and other trained healthcare professionals are eligible to do the screening tests. Intervention after screening is also important and patients detected to have CKD should be referred to primary care and general physicians with experience in management of kidney disease for follow up. A management protocol including referral to nephrologists should be provided to the primary care and general physicians.21, 24, 26 Given the close links between CKD and other NCD, it is critical that CKD advocacy efforts be aligned with existing initiatives concerning diabetes, hypertension and cardiovascular disease, particularly in low middle income countries. Some countries and regions have successfully introduced CKD prevention strategies as part of their NCD programmes. As an example, in 2003, a kidney health promotion programme was introduced in Taiwan, with its key components including a ban on herbs containing aristolochic acid, public awareness campaigns, patient education, funding for CKD research and the setting up of teams to provide integrated care.34 In Cuba, the Ministry of Public Health has implemented a national programme for the prevention of CKD. The integration of CKD prevention into NCD programme has resulted in the reduction of renal and cardiovascular risks in the general population. There has been an increased rate of the diagnosis of diabetes and of glycaemic control, as well as an increased diagnosis of patients with hypertension, higher prescription use of renoprotective treatment with angiotensin converting enzyme inhibitor and higher rates of blood pressure control.35, 36 Recently, the US Department of Health and Human Services has introduced an ambitious programme to reduce the number of Americans developing end-stage renal disease by 25% by 2030. The programme, known as the Advancing American Kidney Health Initiative, has set goals with metrics to measure its success; among them is to put more efforts to prevent, detect and slow the progression of kidney disease, in part by addressing traditional risk factors like diabetes and hypertension.37 Ongoing programmes, like the Special Diabetes Program for Indians, represent an important part of this approach by providing team-based care and care management. Since its implementation, the incidence of diabetes-related kidney failure among American Native populations decreased by over 40% between 2000 and 2015.38 Since 1994, a National Institute of Health consensus advocated for early medical intervention in pre-dialysis patients. Owing to the complexity of care of CKD, it was recommended that patients should be referred to a multidisciplinary team consisting of nephrologist, dietitian, nurse, social worker and health psychologist, with the aim to reduce pre-dialysis and dialysis morbidity and mortality.39 In Mexico, a nurse-led, protocol driven, multidisciplinary programme reported better preservation in eGFR and a trend in the improvement of quality of care of CKD patients similar to those reported by other Multidisciplinary Clinic programmes in the developed world.40 Future models should address region-specific causes of CKD, increase the quality of diagnostic capabilities, establish referral pathways and provide better assessments of clinical effectiveness and cost-effectiveness.41 e-Learning has also become an increasingly popular approach to medical education. Online learning programmes for NCD prevention and treatment, including CKD, have been successfully implemented in Mexico. By 2015, over 5000 health professionals (including non-nephrologists) had been trained using an electronic health education platform.42 It is equally important to promote ‘Prevention’ with education programmes for those at risk of kidney disease and with the general population at large. Education is key to engaging patients with kidney disease. It is the path to self-management and patient-centred care. Narva et al.43 found that patient education is associated with better patient outcomes. Obstacles include the complex nature of kidney disease information, low baseline awareness, limited health literacy, limited availability of CKD information and lack of readiness to learn. Schatell44 found web-based kidney education is helpful in supporting patient self-management. Reputable healthcare organisations should facilitate users to have easier access to health information on their websites (Appendix S1). Engagements of professional society, patient groups, charitable and philanthropic organisations promote community partnership and patient empowerment on prevention. ‘Kidney Health for Everyone, Everywhere’ should be a policy imperative that can be successfully achieved if policy makers, nephrologists, healthcare professionals and the general public place prevention and primary care for kidney disease within the context of their Universal Health Coverage programmes. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.